Results 101 to 110 of about 26,166,385 (205)

3D Pharmacophore Modeling Techniques in Computer-Aided Molecular Design Using LigandScout

open access: yes, 2017
This chapter reviews theory related to pharmacophore models and guide the user through six essential workflows using LigandScout: structure‐based pharmacophore modeling, ligand‐based pharmacophore modeling, creating shared‐feature pharmacophore models ...
Poli, Giulio   +9 more
core   +1 more source

Integrated molecular medicine approaches in inflammation: pharmacoinformatic modelling, virtual screening, 3D-QSAR and free energy landscape analysis of dronedarone derivatives for targeting NLRP3 inflammasome

open access: yesDiscover Applied Sciences
Chronic inflammatory diseases are the most significant cause of death in the world. NLRP3 is an attractive target for the design of anti-inflammatory agents.
Trupti Sameer Chitre   +8 more
doaj   +1 more source

E-Pharmacophore and virtual screening reveal Apium graveolens as a therapeutic prospect for vitiligo

open access: yesResults in Chemistry
Vitiligo is a skin depigmentation disorder resulting from an autoimmune response targeting melanocytes. A polygenic and multifactorial skin disease, which caused by association of oxidative stress, autoimmune, genetics, neurological system dysfunction ...
Femina Jamal Mohamed   +6 more
doaj   +1 more source

Parallel Screening:  A Novel Concept in Pharmacophore Modeling and Virtual Screening†

open access: yes, 2016
Parallel screening comprises a novel in silico method to predict the potential biological activities of a compound by screening it with a multitude of pharmacophore models. Our aim is to provide a fast, large-scale system that allows for virtual activity
Theodora M. Steindl (2452300)   +3 more
core   +1 more source

Identification of Potential Multitarget Compounds against Alzheimer's Disease through Pharmacophore-Based Virtual Screening. [PDF]

open access: yesPharmaceuticals (Basel), 2023
Mendes GO   +13 more
europepmc   +1 more source

Workflow illustration for pharmacophore-based 3D QSAR modeling and virtual screening to identify compounds with antagonistic activities against A2A.

open access: yes, 2019
Workflow illustration for pharmacophore-based 3D QSAR modeling and virtual screening to identify compounds with antagonistic activities against A2A.
Hisham K. Hamadeh (13317)   +3 more
core   +1 more source

Allosteric modulators of metabotropic glutamate receptors: from virtual screening to experimental validation [PDF]

open access: yes, 2007
The goal of this thesis was to gain further insight into the binding behavior of ligands in the heptahelical domain (HD) of group I metabotropic glutamate receptors (mGluRs).
Noeske, Tobias
core  

Discovery of Novel Focal Adhesion Kinase Inhibitors Using a Hybrid Protocol of Virtual Screening Approach Based on Multicomplex-Based Pharmacophore and Molecular Docking

open access: yes, 2012
Focal adhesion kinase (FAK) is a tyrosine kinase that functions as a key orchestrator of signals leading to invasion and metastasis. In the current study, the multicomplex-based pharmacophore (MCBP)-guided method has been suggested to generate a ...
Cheng Peng   +7 more
core   +1 more source

Pharmacophore-based identification and molecular docking of CCR5 inhibitors: insights from dynamic simulations

open access: yes
The chemokine receptor type 5 (CCR5) plays a crucial role in HIV-1 entry into host cells, making it a key therapeutic target. This study aimed to identify novel CCR5 inhibitors through pharmacophore-guided virtual screening and molecular dynamics (MD ...
Angadi Sathish Kumar (24374720)   +1 more
core   +1 more source

In silico study of structure-based screening of inhibitors to block PrPC conversion and amyloid aggregation

open access: yesFrontiers in Chemical Biology
Prion diseases are a group of progressive and fatal neurodegenerative diseases, caused by the transformation of cellular prion protein (PrPC) into a misfolded pathogenic isoform (PrPSc).
Kamakshi Ruhela   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy